Uncategorized
ENV515 from Envisia meets primary efficacy endpoint in phase 2a glaucoma trial
ENV515 achieved its primary efficacy endpoint in reducing IOP in a phase 2a glaucoma clinical trial, according to an Envisia Therapeutics press release.The propriety, fully biodegradable PRINT travoprost formulation is designed to sustain IOP reductions for more than 6 months after a single dose without the need for additional eye drops.